Xcout Intel
NeoGenomics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to NeoGenomics, Inc. among biotech companies — ranked by similarity to what NeoGenomics, Inc. actually does, not by market-cap band.
Subscribe to see NeoGenomics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About NeoGenomics, Inc.
NeoGenomics, Inc. is a specialized clinical laboratory company headquartered in Fort Myers, Florida. It operates a network of CAP-accredited and CLIA-certified laboratories to provide comprehensive oncology testing and sample processing services.
NeoGenomics, Inc. at a glance
NeoGenomics, Inc. is a biotech company headquartered in Fort Myers, United States. It is publicly listed (NEO) with a market capitalisation of $474.6M. Xcout tracks 31 named people at NeoGenomics, Inc., including Anthony Zook (Chief Executive Officer & Director). Xcout recorded 1 job posting from NeoGenomics, Inc. in the last 90 days.
NeoGenomics, Inc. leadership
- Anthony ZookChief Executive Officer & Director
- Tony ZookChief Executive Officer
- Warren StonePresident & Chief Operating Officer
- Abhishek JainExecutive VP & CFO
- Kristi McKeownChief Commercial Officer
- Gary PassmanChief People & Culture Officer
25 more named people on record for NeoGenomics, Inc., with roles, board committees and tenure — see the full roster →
Hiring at NeoGenomics, Inc.
Xcout recorded 1 job posting from NeoGenomics, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see NeoGenomics, Inc.'s hiring signals →
Top 12 NeoGenomics, Inc. competitors
Ranked by semantic similarity — how close each company is to NeoGenomics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Healthcare & Biotechnology
NxGen MDx is a privately held medical consulting and genetic screening company headquartered in Grand Rapids, Michigan, offering specialized laboratory and diagnostic testing services.
Biotechnology
Cancer Genetics, Inc. is a biotechnology company headquartered in Rutherford, New Jersey, with operational history including facilities in Los Angeles, California. The company provides specialized oncology-focused diagnostic products, genomic services, and biomarker testing.
Similar biotech company
Foundation Medicine, Inc. is an American company based in Boston, Massachusetts, which develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas.
Medical - Diagnostics & Research
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Similar biotech company
Invitae Corp. is a biotechnology company specializing in genetic testing and laboratory services. The firm has operated with a significant operational footprint and experienced corporate acquisitions within the healthcare market.
Biotechnology
Nexome Genomics provides cloud-based, integrated analytics solutions that process next-generation sequencing data for healthcare institutions. The company enables hospitals, medical centers, and physician offices to generate on-demand diagnostic and prognostic reports for precision medicine.
Similar biotech company
Source BioScience is a UK-based laboratory services company providing genomics, DNA sequencing, molecular diagnostics, and pathology-related testing. It serves pharmaceutical and biotechnology companies, healthcare organizations, research institutions, and other life-science customers.
Biotechnology
Nexosome Oncology Holdings, Inc. develops blood tests for early-stage cancer detection using patented extracellular vesicle proteomics and AI/ML biomarker discovery. The company serves patients and healthcare partners by providing highly accurate diagnostic tools.
Biotechnology
TAI Diagnostics, Inc. is a diagnostic laboratory company specializing in specialized genetic panel tests and pathology services within the healthcare sector.
Similar biotech company
IntegraGen develops genomic tests, molecular diagnostic products, and bioinformatics software for researchers, clinicians, and biopharma companies. The company specializes in oncology and genetic diseases, offering next-generation sequencing services, data analysis tools, and biomarker identification to support clinical research and diagnostics.
Medical - Diagnostics & Research
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
Biotechnology
Capio Biosciences is an oncology diagnostics company that develops advanced technologies for capturing and analyzing circulating tumor cells (CTCs) from whole blood. Its proprietary CapioCyte platform offers enhanced sensitivity compared to traditional methods, serving as a research tool designed to help oncologists make informed cancer treatment decisions.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of NeoGenomics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for NeoGenomics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →